Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Oral Mucositis: Etiology and Clinical and Pharmaceutical Management

Author(s):  Zur Eyal

Issue:  Jan/Feb 2012 - Volume 16, Number 1
View All Articles in Issue

Page(s):  22-33

Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 1
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 2
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 3
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 4
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 5
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 6
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 7
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 8
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 9
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 10
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 11
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Page 12

Download in electronic PDF format for $75

Abstract:  Oral mucosal damage is one of the common and worst side effects of radiotherapy and chemotherapy treatment for cancer. With prevalence between 10% and 100%, depending on the cytotoxic and/or radiotherapy regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. This article addresses oral mucositis and discusses its prevalence, risk factors, clinical and economical impacts, etiology, and clinical management in view of the most recent evidence. Despite clear progress and the development of clinical guidelines on this topic, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. This article offers two compounded preparations supported by evidence-based data to treat oral mucositis. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies.

Related Keywords: Eyal Zur, RPh, MBA, formulation, cancer chemotherapy, radiation therapy, hematopoietic stem cell transplant, mucous membranes, mouth ulcers, mouth ulceration, stomatitis, risk factors, prevention, keratinocyte growth factor 1, KGF-1, cryotherapy, dry mouth, xerostomia, laser therapy, benzydamine hydrochloride, morphine hydrochloride mouthwash

Related Categories: CANCER AND AIDS, EAR NOSE THROAT, FORMULATIONS, PAIN MANAGEMENT, ALLERGY/IMMUNOLOGY/INFLAMMATION, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management
Zur Eyal
Jan/Feb 2012
Pg. 22-33

Case Report: Lidocaine Mucoadhesive Buccal Tablets for Local Relief of Mouth Ulcers
Young Jennifer L
, Bogner Robin H
May/Jun 2009
Pg. 214-217

Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum
Zur Eyal
Mar/Apr 2012
Pg. 117-124

Burning Mouth Syndrome: A Discussion of a Complex Pathology
Zur Eyal
May/Jun 2012
Pg. 196-205

Basics of Compounding for the Treatment of Warts
Allen Loyd V Jr
Mar/Apr 2004
Pg. 126-129

Compounding for the Dental Patient: A Focus on Ulcers of the Mouth
Bassani August S
, Keim David
Nov/Dec 2004
Pg. 436-440

A Review of Stomatitis and Treatment in Cats
Ray Jody D
, Jordan Dinah G, Eubanks Diana L, Crosswhite Megan E
Sep/Oct 2009
Pg. 372-381

Surviving Cancer - How the Compounding Pharmacist Can Help
Maddox Suzan
Jul/Aug 2000
Pg. 257-260

Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
Nov/Dec 2012
Pg. 462-469

Misoprostol 0.0024% Mouth Rinse for Oral Ulcerations
Allen Loyd V Jr
Jul/Aug 2000
Pg. 302

Ketoprofen 100-mg/5-mL Mouth Rinse
Allen Loyd V Jr
Jan/Feb 2010
Pg. 68

Effects of Compounded Stanford Modified Oral Rinse (MucoLox) on the Survival and Migration of Oral Keratinocytes and Fibroblasts: Implications for Wound Healing
Song Guiyun
, Banov Daniel, Bassani August S
Jan/Feb 2018
Pg. 60-65

The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 1
Williams LaVonn
Jul/Aug 2018
Pg. 284-287

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Basics of Compounding: Clinical Studies
Allen Loyd V Jr
Nov/Dec 2002
Pg. 443-447

Collaborative Drug Therapy Management and its Application to Pharmaceutical Compounding
Anderson Derick
Jan/Feb 2007
Pg. 56-58

Stability of Tranexamic Acid Mouth Rinse
Donnelly Ronald F
Sep/Oct 2018
Pg. 412-416

The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2
Williams LaVonn A
Jan/Feb 2019
Pg. 14-21

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Return to Top